Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985000 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL7446481 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL28416333 | 0.96 | FOLH1 (0.49) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL24765399 | 0.88 | FOLH1 (0.54) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL14845338 | 0.85 | SIRT6 (0.42) | FOLH1GSRCPB2RNPEPMMP9 | |
| SCHEMBL20887997 | 0.85 | FOLH1 (0.41) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL22859968 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL10047161 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL13891963 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL25602464 | 0.82 | NOD1 (0.49) | SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | FOLH1 4072/4885GSR 4689/4885CPB2 3158/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | FOLH1 4072/4885GSR 4689/4885CPB2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.